Ipsen (IPN.PA) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

IPN.PA · Stock Price

EUR 168.50+66.80 (+65.68%)

Market Cap: $16.2B

Historical price data

Market Cap: $16.2BPipeline: 200 drugs (101 Phase 3)Patents: 20Founded: 1986HQ: Paris, France

Sector Ranking#68 in Biologics / Biosimilars #12 in Rare & Orphan Diseases

Overview

Ipsen is a global specialty-care biopharmaceutical company with a focused mission to develop and commercialize innovative medicines in oncology, rare diseases, and neuroscience. Under CEO David Loew, the company has achieved strong commercial execution, delivering over 9% sales growth in 2024 and upgrading guidance in 2025, underpinned by a robust balance sheet and investment-grade credit ratings. Its strategy centers on deep therapeutic area specialization, a balanced internal and external innovation model, and leveraging its unique toxin platform to build a sustainable, high-growth pipeline.

OncologyRare DiseasesNeuroscience

Technology Platform

Ipsen's technology foundation is built on three deep, experience-based platforms: a 35+ year oncology platform specializing in neuroendocrine tumors and pediatric cancers, a 30+ year neuroscience platform centered on proprietary toxin (botulinum) expertise, and a rare disease platform focused on navigating complex development pathways for niche indications.

Pipeline

200

200 drugs in pipeline101 in Phase 3

Drug	Indication	Stage
Botulinum toxin type A	Hemifacial Spasm	Phase 3
BLI800 + Fortrans®	Diagnosis Disease	Phase 3
Lanreotide + saline	Autosomal Dominant Polycystic Kidney Disease (ADPKD	Phase 3
lanreotide (Autogel formulation) + Pegvisomant	Acromegaly	Phase 3
rh IGF-1 (mecasermin)	Growth Disorders	Phase 3

Funding History

1

IPOUndisclosedUndisclosedJun 15, 2005

FDA Approved Drugs

6

IQIRVONDAJun 10, 2024

SOHONOSNDAAug 16, 2023

BYLVAYNDAJul 20, 2021

Opportunities

Significant opportunities exist in the expansion of its rare liver disease franchise, the successful launch of new oncology assets like IPN60340 in AML, and geographic/market share growth for its core Dysport® franchise.

The company's strong cash flow and balance sheet provide ample resources for strategic, pipeline-enhancing partnerships and M&A.

Risk Factors

Key risks include clinical and regulatory setbacks in the late-stage pipeline, revenue concentration in a few key products facing long-term patent expiry, and sustained pricing pressure across all therapeutic areas, particularly in the competitive U.S.

market.

Competitive Landscape

Ipsen competes in specialized, often duopolistic or oligopolistic markets: against Novartis in NETs, AbbVie in neuromodulator toxins, and Intercept in rare liver disease. Its competitive edge stems from deep therapeutic area expertise, integrated global commercial capabilities, and the high technical barriers of its toxin platform.